Sign in
CompletedPhase 3

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Key facts

Who runs it
Pfizer
Where
Chicago, Lake Success, Los Angeles, New Hyde Park, and Phoenix, United StatesSee the 5 sitesAlso in 18 other countries, 46 sites
Status
Completed
Phase
Phase 3
People taking part
100 people enrolled
Started
10 May 2018
Ended
27 Mar 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • In open-label phase: treatment with tofacitinib
  • In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Record updated
3 June 2025

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • active sJIA disease according to ILAR criteria before screening and at baseline (Day 1)
  • Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted
  • Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted

Who cannot take part

  • Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib
  • Current infection or serious infection within 3 months of study enrollment
  • Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA

Where in United States

Also in 18 other countries, 46 sites

  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
  • Cohen Children's Medical Center of New YorkLake Success, United States
  • Children's Hospital Los AngelesLos Angeles, United States
  • Cohen Children's Medical Center of New YorkNew Hyde Park, United States
  • Phoenix Children s HospitalPhoenix, United States

About the trial

What the trial wants to find out

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.

The 2 groups in the trial

  • Tofacitinib 5 mg BIDTreatment being tested

    oral, twice daily, tablet or solution.

    Treatment: In open-label phase: treatment with tofacitinib and In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

  • PlaceboPlacebo, for comparison

    Treatment: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
Record updated
3 June 2025